JP2013534535A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013534535A5 JP2013534535A5 JP2013519199A JP2013519199A JP2013534535A5 JP 2013534535 A5 JP2013534535 A5 JP 2013534535A5 JP 2013519199 A JP2013519199 A JP 2013519199A JP 2013519199 A JP2013519199 A JP 2013519199A JP 2013534535 A5 JP2013534535 A5 JP 2013534535A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- tumor
- disease
- lymphoma
- sclc
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010028980 Neoplasm Diseases 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 206010041067 Small cell lung cancer Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 206010061424 Anal cancer Diseases 0.000 claims 1
- 208000007860 Anus Neoplasms Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010007953 Central nervous system lymphoma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 claims 1
- 230000002491 angiogenic effect Effects 0.000 claims 1
- 201000011165 anus cancer Diseases 0.000 claims 1
- 210000000013 bile duct Anatomy 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 210000003238 esophagus Anatomy 0.000 claims 1
- 210000000232 gallbladder Anatomy 0.000 claims 1
- 210000003128 head Anatomy 0.000 claims 1
- 210000003026 hypopharynx Anatomy 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 210000000244 kidney pelvis Anatomy 0.000 claims 1
- 210000002429 large intestine Anatomy 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 210000003739 neck Anatomy 0.000 claims 1
- 201000011682 nervous system cancer Diseases 0.000 claims 1
- 206010061311 nervous system neoplasm Diseases 0.000 claims 1
- 210000003300 oropharynx Anatomy 0.000 claims 1
- 210000001672 ovary Anatomy 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- 208000016800 primary central nervous system lymphoma Diseases 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 206010038038 rectal cancer Diseases 0.000 claims 1
- 210000000664 rectum Anatomy 0.000 claims 1
- 201000001275 rectum cancer Diseases 0.000 claims 1
- 210000000813 small intestine Anatomy 0.000 claims 1
- 210000002784 stomach Anatomy 0.000 claims 1
- 210000001685 thyroid gland Anatomy 0.000 claims 1
- 210000000626 ureter Anatomy 0.000 claims 1
- 210000002936 ureteral cell Anatomy 0.000 claims 1
- 210000003932 urinary bladder Anatomy 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36350710P | 2010-07-12 | 2010-07-12 | |
| US61/363,507 | 2010-07-12 | ||
| PCT/IB2011/053092 WO2012007896A1 (en) | 2010-07-12 | 2011-07-11 | Multifunctional antibody conjugates |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015248537A Division JP6339995B2 (ja) | 2010-07-12 | 2015-12-21 | 多機能性抗体複合体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013534535A JP2013534535A (ja) | 2013-09-05 |
| JP2013534535A5 true JP2013534535A5 (OSRAM) | 2014-03-20 |
| JP5913307B2 JP5913307B2 (ja) | 2016-04-27 |
Family
ID=44630490
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013519199A Active JP5913307B2 (ja) | 2010-07-12 | 2011-07-11 | 多機能性抗体複合体 |
| JP2015248537A Active JP6339995B2 (ja) | 2010-07-12 | 2015-12-21 | 多機能性抗体複合体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015248537A Active JP6339995B2 (ja) | 2010-07-12 | 2015-12-21 | 多機能性抗体複合体 |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US8741291B2 (OSRAM) |
| EP (1) | EP2593142B8 (OSRAM) |
| JP (2) | JP5913307B2 (OSRAM) |
| KR (1) | KR20130050966A (OSRAM) |
| CN (1) | CN103096933A (OSRAM) |
| AR (1) | AR082205A1 (OSRAM) |
| AU (1) | AU2011277999A1 (OSRAM) |
| BR (1) | BR112013000951A2 (OSRAM) |
| CA (1) | CA2804185C (OSRAM) |
| CO (1) | CO6670522A2 (OSRAM) |
| ES (1) | ES2704223T3 (OSRAM) |
| MX (1) | MX2013000491A (OSRAM) |
| PE (1) | PE20130643A1 (OSRAM) |
| PH (1) | PH12013500070A1 (OSRAM) |
| RU (1) | RU2012157167A (OSRAM) |
| SG (1) | SG186451A1 (OSRAM) |
| TW (1) | TWI432213B (OSRAM) |
| WO (1) | WO2012007896A1 (OSRAM) |
| ZA (1) | ZA201300161B (OSRAM) |
Families Citing this family (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2013118441A (ru) | 2010-11-05 | 2014-12-10 | КовЭкс Текнолоджиз Айэлэнд Лимитед | Антидиабетические соединения |
| CA2836927A1 (en) * | 2011-06-21 | 2012-12-27 | Immunogen, Inc. | Novel maytansinoid derivatives with peptide linker and conjugates thereof |
| PT3327027T (pt) | 2011-11-17 | 2021-02-15 | Pfizer | Péptidos citotóxicos e seus conjugados de anticorpos e fármacos |
| TW201341401A (zh) * | 2012-01-09 | 2013-10-16 | Covx Technologies Ireland Ltd | 突變抗體及其共軛 |
| KR102498405B1 (ko) | 2012-10-11 | 2023-02-09 | 다이이찌 산쿄 가부시키가이샤 | 글리신아미드 화합물의 제조 방법 |
| WO2014061277A1 (ja) | 2012-10-19 | 2014-04-24 | 第一三共株式会社 | 親水性構造を含むリンカーで結合させた抗体－薬物コンジュゲート |
| AU2013343111A1 (en) | 2012-11-07 | 2015-05-14 | Pfizer Inc. | Anti-IL-13 receptor alpha 2 antibodies and antibody-drug conjugates |
| BR112015010436A2 (pt) | 2012-11-07 | 2017-08-22 | Pfizer | Anticorpos anti-notch3 e conjugados anticorpo-fármaco |
| AU2013342163B2 (en) | 2012-11-08 | 2018-08-16 | F. Hoffmann-La Roche Ltd | IL-6 antagonists and uses thereof |
| EP2922818B1 (en) | 2012-11-24 | 2018-09-05 | Hangzhou Dac Biotech Co., Ltd | Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules |
| WO2015057066A1 (en) * | 2013-10-14 | 2015-04-23 | Synaffix B.V. | Glycoengineered antibody, antibody-conjugate and methods for their preparation |
| EP2935608A1 (en) * | 2013-10-14 | 2015-10-28 | SynAffix B.V. | Modified glycoprotein, protein-conjugate and process for the preparation thereof |
| PT3088419T (pt) | 2013-12-25 | 2019-01-11 | Daiichi Sankyo Co Ltd | Conjugado de anticorpo anti-trop2-fármaco |
| CA2928794C (en) * | 2014-01-31 | 2019-08-13 | Daiichi Sankyo Company, Limited | Anti-her2 antibody-drug conjugate |
| AU2014384434B2 (en) | 2014-02-28 | 2016-11-03 | Hangzhou Dac Biotech Co., Ltd | Charged linkers and their uses for conjugation |
| WO2015155976A1 (ja) | 2014-04-10 | 2015-10-15 | 第一三共株式会社 | 抗ｈｅｒ２抗体－薬物コンジュゲート |
| RU2711640C2 (ru) | 2014-04-10 | 2020-01-17 | Дайити Санкио Компани, Лимитед | Конъюгат анти-her3 антитело-лекарственное средство |
| DK4268843T3 (da) | 2014-11-07 | 2025-11-10 | F Hoffmann La Roche Ltd | Forbedrede IL-6-antistoffer |
| CA2986486C (en) * | 2015-05-20 | 2023-03-07 | Immunwork Inc. | Molecular constructs with targeting and effector elements and their applications |
| LT3310816T (lt) * | 2015-06-19 | 2020-11-25 | Eisai R&D Management Co., Ltd. | Cys80 konjuguoti imunoglobulinai |
| CN107922477B (zh) | 2015-06-29 | 2022-11-01 | 第一三共株式会社 | 用于选择性制造抗体-药物缀合物的方法 |
| TWI617319B (zh) * | 2015-09-01 | 2018-03-11 | 免疫功坊股份有限公司 | 用以治療病理性血栓的融合蛋白 |
| US11197934B2 (en) * | 2015-09-17 | 2021-12-14 | The Scripps Research Institute | Dual variable domain immunoconjugates and uses thereof |
| AU2016341321A1 (en) * | 2015-10-23 | 2018-06-07 | Sorrento Therapeutics, Inc. | Programmable universal cell receptors and methods of using the same |
| CN106729743B (zh) | 2015-11-23 | 2021-09-21 | 四川科伦博泰生物医药股份有限公司 | 抗ErbB2抗体-药物偶联物及其组合物、制备方法和应用 |
| US20220008553A1 (en) * | 2015-11-23 | 2022-01-13 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Anti-erbb2 antibody-drug conjugate and composition thereof, preparation method therefor, and use thereof |
| CN107029244B (zh) * | 2016-02-04 | 2021-04-27 | 浙江昭华生物医药有限公司 | 抗her2抗体-药物偶联物及其应用 |
| EP3413921A4 (en) | 2016-02-09 | 2019-08-14 | Alexander Krantz | LOCAL ACTIVE FUNCTIONALIZATION OF PROTEINS BY MEANS OF TRANSPARENT AFFINITY MARKINGS |
| US20190046642A1 (en) * | 2016-02-23 | 2019-02-14 | Eleven Biotherapeutics, Inc. | Il-6 antagonist formulations and uses thereof |
| IL263616B2 (en) | 2016-07-07 | 2025-01-01 | Univ Leland Stanford Junior | Antibody-adjuvant conjugates |
| US11273155B2 (en) | 2016-12-12 | 2022-03-15 | Daiichi Sankyo Company, Limited | Combination of antibody-drug conjugate and immune checkpoint inhibitor |
| KR102537651B1 (ko) | 2017-01-17 | 2023-05-26 | 다이이찌 산쿄 가부시키가이샤 | 항 gpr20 항체 및 항 gpr20 항체-약물 콘쥬게이트 |
| CA3051038C (en) | 2017-01-24 | 2022-07-26 | Pfizer Inc. | Calicheamicin derivatives and antibody drug conjugates thereof |
| TW202530219A (zh) | 2017-05-15 | 2025-08-01 | 日商第一三共股份有限公司 | 抗體－藥物結合物之製造方法 |
| WO2019044946A1 (ja) | 2017-08-31 | 2019-03-07 | 第一三共株式会社 | 抗体－薬物コンジュゲートの新規製造方法 |
| AU2018327171B2 (en) | 2017-08-31 | 2023-03-09 | Daiichi Sankyo Company, Limited | Improved method for producing antibody-drug conjugate |
| JP2021502418A (ja) * | 2017-11-04 | 2021-01-28 | アドバンスト・プロテオーム・セラピューティクス・インコーポレイテッド | ポリペプチドを修飾するための組成物及び方法 |
| JP7339262B2 (ja) | 2018-01-12 | 2023-09-05 | アムジェン インコーポレイテッド | Ｐａｃ１抗体及びその使用 |
| BR112020023373A2 (pt) | 2018-05-18 | 2021-02-09 | Daiichi Sankyo Company, Limited | conjugado, composição, e, uso de um conjugado ou de uma composição |
| TWI846717B (zh) | 2018-07-27 | 2024-07-01 | 日商第一三共股份有限公司 | 辨識抗體-藥物結合物之藥物部位的蛋白質 |
| US12220604B2 (en) | 2018-07-31 | 2025-02-11 | Daiichi Sankyo Company, Limited | Treatment of metastatic brain tumor by administration of an antibody-drug conjugate |
| US12018087B2 (en) | 2018-08-02 | 2024-06-25 | Dyne Therapeutics, Inc. | Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject |
| US20210308273A1 (en) | 2018-08-02 | 2021-10-07 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US11911484B2 (en) | 2018-08-02 | 2024-02-27 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US11168141B2 (en) | 2018-08-02 | 2021-11-09 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US12097263B2 (en) | 2018-08-02 | 2024-09-24 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| JP2021533200A (ja) | 2018-08-02 | 2021-12-02 | ダイン セラピューティクス, インコーポレーテッドDyne Therapeutics, Inc. | 顔面・肩甲・上腕筋ジストロフィーを処置するための筋標的化複合体およびそれらの使用 |
| AU2020241686A1 (en) | 2019-03-15 | 2021-11-04 | Bolt Biotherapeutics, Inc. | Immunoconjugates targeting HER2 |
| KR20220045047A (ko) * | 2019-08-19 | 2022-04-12 | 션양 파마슈티컬 유니버시티 | 항체 변이체 및 이의 적용 |
| EP4025255A1 (en) | 2019-09-04 | 2022-07-13 | Bolt Biotherapeutics, Inc. | Immunoconjugate synthesis method |
| EP4366784A1 (en) | 2021-07-09 | 2024-05-15 | Dyne Therapeutics, Inc. | Muscle targeting complexes and formulations for treating dystrophinopathies |
| US11969475B2 (en) | 2021-07-09 | 2024-04-30 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| US11638761B2 (en) | 2021-07-09 | 2023-05-02 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy |
| US11648318B2 (en) | 2021-07-09 | 2023-05-16 | Dyne Therapeutics, Inc. | Anti-transferrin receptor (TFR) antibody and uses thereof |
| US11771776B2 (en) | 2021-07-09 | 2023-10-03 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| WO2023288033A1 (en) | 2021-07-14 | 2023-01-19 | Lycia Therapeutics, Inc. | Asgpr cell surface receptor binding compounds and conjugates |
| IL312142A (en) * | 2021-11-01 | 2024-06-01 | Dyne Therapeutics Inc | Muscle targeting complexes for the treatment of dystrophinopathy |
| KR20250004769A (ko) * | 2022-04-15 | 2025-01-08 | 다인 세라퓨틱스, 인크. | 근긴장성 이영양증을 치료하기 위한 근육 표적화 복합체 및 그의 용도 |
| KR20250004770A (ko) | 2022-04-15 | 2025-01-08 | 다인 세라퓨틱스, 인크. | 근긴장성 이영양증을 치료하기 위한 근육 표적화 복합체 및 제제 |
| JP2025537044A (ja) | 2022-09-30 | 2025-11-13 | シャンハイ ドーァ ノボ ファーマテック カンパニー，リミティド | ベンザゼピン誘導体、それを含む複合体およびその応用 |
| CN120603814A (zh) | 2023-02-28 | 2025-09-05 | 四川科伦博泰生物医药股份有限公司 | 一类化学偶联连接子及其用途 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5733757A (en) | 1995-12-15 | 1998-03-31 | The Scripps Research Institute | Aldolase catalytic antibody |
| WO2001027145A1 (en) | 1999-10-08 | 2001-04-19 | The Scripps Research Institute | Antibody catalysis of enantio- and diastereo-selective aldol reactions |
| AR032028A1 (es) | 2001-01-05 | 2003-10-22 | Pfizer | Anticuerpos contra el receptor del factor de crecimiento similar a insulina |
| KR20040058229A (ko) | 2001-10-22 | 2004-07-03 | 더 스크립스 리서치 인스티튜트 | 항체 표적화 화합물 |
| US7217845B2 (en) * | 2002-11-25 | 2007-05-15 | Sun Bio, Inc. | Bifunctional polyethylene glycol derivatives |
| AR046071A1 (es) | 2003-07-10 | 2005-11-23 | Hoffmann La Roche | Anticuerpos contra el receptor i del factor de crecimiento de tipo insulinico y los usos de los mismos |
| CN1835975B (zh) | 2003-08-13 | 2012-11-21 | 辉瑞产品公司 | 经修饰的人类igf-1r抗体 |
| JP5167473B2 (ja) | 2005-03-03 | 2013-03-21 | コヴェックス・テクノロジーズ・アイルランド・リミテッド | 抗血管新生化合物 |
| KR20120043028A (ko) | 2006-11-10 | 2012-05-03 | 씨오브이엑스 테크놀로지스 아일랜드 리미티드 | 혈관 신생 억제 화합물 |
| US20090098130A1 (en) | 2007-01-05 | 2009-04-16 | Bradshaw Curt W | Glucagon-like protein-1 receptor (glp-1r) agonist compounds |
| CN101842117A (zh) | 2007-08-28 | 2010-09-22 | 比奥根艾迪克Ma公司 | 抗igf-1r抗体及其用途 |
| GEP20156390B (en) | 2008-01-03 | 2015-11-10 | Scripps Research Inst | Antibody targeting through a modular recognition domain |
| US8293714B2 (en) * | 2008-05-05 | 2012-10-23 | Covx Technology Ireland, Ltd. | Anti-angiogenic compounds |
| US8268314B2 (en) | 2008-10-08 | 2012-09-18 | Hoffmann-La Roche Inc. | Bispecific anti-VEGF/anti-ANG-2 antibodies |
-
2011
- 2011-07-11 EP EP11745833.1A patent/EP2593142B8/en active Active
- 2011-07-11 ES ES11745833T patent/ES2704223T3/es active Active
- 2011-07-11 AU AU2011277999A patent/AU2011277999A1/en not_active Abandoned
- 2011-07-11 BR BR112013000951A patent/BR112013000951A2/pt not_active Application Discontinuation
- 2011-07-11 SG SG2012094983A patent/SG186451A1/en unknown
- 2011-07-11 RU RU2012157167/10A patent/RU2012157167A/ru not_active Application Discontinuation
- 2011-07-11 CN CN2011800438472A patent/CN103096933A/zh active Pending
- 2011-07-11 JP JP2013519199A patent/JP5913307B2/ja active Active
- 2011-07-11 WO PCT/IB2011/053092 patent/WO2012007896A1/en not_active Ceased
- 2011-07-11 PH PH1/2013/500070A patent/PH12013500070A1/en unknown
- 2011-07-11 AR ARP110102486A patent/AR082205A1/es not_active Application Discontinuation
- 2011-07-11 KR KR1020137003413A patent/KR20130050966A/ko not_active Ceased
- 2011-07-11 PE PE2013000052A patent/PE20130643A1/es not_active Application Discontinuation
- 2011-07-11 MX MX2013000491A patent/MX2013000491A/es unknown
- 2011-07-11 CA CA2804185A patent/CA2804185C/en active Active
- 2011-07-12 TW TW100124612A patent/TWI432213B/zh not_active IP Right Cessation
- 2011-11-28 US US13/305,354 patent/US8741291B2/en active Active
-
2013
- 2013-01-07 ZA ZA2013/00161A patent/ZA201300161B/en unknown
- 2013-01-11 CO CO13004943A patent/CO6670522A2/es unknown
-
2015
- 2015-12-21 JP JP2015248537A patent/JP6339995B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013534535A5 (OSRAM) | ||
| Haendler et al. | Recent developments in antiandrogens and selective androgen receptor modulators | |
| Abou-Antoun et al. | Brain cancer stem cells in adults and children: cell biology and therapeutic implications | |
| Spano et al. | Molecular networks that regulate cancer metastasis | |
| Azevedo et al. | Emerging antibody-based therapeutic strategies for bladder cancer: A systematic review | |
| JP2010536719A5 (OSRAM) | ||
| Song et al. | Development of small molecules targeting the Wnt signaling pathway in cancer stem cells for the treatment of colorectal cancer | |
| JP2010532774A5 (OSRAM) | ||
| JP2011126896A5 (OSRAM) | ||
| JP2010209101A5 (OSRAM) | ||
| RU2016108667A (ru) | Комбинированная терапия для лечения рака | |
| JP2016528246A5 (OSRAM) | ||
| RU2013134359A (ru) | Комбинированная терапия с применением индуктора и ингибитора аутофагии для лечения новообразований | |
| EP2170062A4 (en) | METHOD AND COMPOSITIONS FOR THE TREATMENT OF CANCER DISORDERS, TUMORS AND TUMOR-DISORDED DISEASES | |
| JP2011157399A5 (OSRAM) | ||
| JP2010516626A5 (OSRAM) | ||
| JP2017536397A5 (OSRAM) | ||
| JP2014005265A5 (OSRAM) | ||
| WO2012170804A9 (en) | Treatments for gastrointestinal disorders | |
| MX2021005784A (es) | Compuestos que inhiben de manera selectiva y efectiva la biquitinación mediada por hakai, como fármacos anti-cáncer. | |
| FR2910324B1 (fr) | Nouveau medicament pour le traitement d'un cancer gastrique | |
| MX2010003988A (es) | Compuesto de isoxazol para el tratamiento de cancer. | |
| JP2016500649A5 (OSRAM) | ||
| RU2016132400A (ru) | Комбинация производного 6-оксо-1,6-дигидро-пиридазина, имеющего противораковую активность, с гефитинибом | |
| JP2017518967A5 (OSRAM) |